Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
CGEN
Compugen
$1.47
Chart
$1.4 (+5.00%)
$1.66 (-11.45%)
$2.47 (-40.49%)
$2.07 (-28.99%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
CGEN
Compugen
Current Price
$1.47
Login to view Compugen (CGEN) recommendation from the last 90 days from financial news and social media.
Chart
$1.4 (+5.00%)
$1.66 (-11.45%)
$2.47 (-40.49%)
$2.07 (-28.99%)
CGEN Latest Headlines
Compugen Reports First Quarter 2025 Results. Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASC
Mon May 19, 2025
Compugen Reports First Quarter 2025 Results. Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASC
Mon May 19, 2025
Compugen Reports First Quarter 2025 Results. Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASC
Mon May 19, 2025
Compugen Reports First Quarter 2025 Results. Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASC
Mon May 19, 2025
Compugen Reports First Quarter 2025 Results. Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASC
Mon May 19, 2025
Compugen Reports First Quarter 2025 Results. Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASC
Mon May 19, 2025
Compugen Reports First Quarter 2025 Results. Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASC
Mon May 19, 2025
Compugen Reports First Quarter 2025 Results. Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASC
Mon May 19, 2025
Compugen Reports First Quarter 2025 Results. Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASC
Mon May 19, 2025
Compugen Reports First Quarter 2025 Results. Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503) a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASC
Mon May 19, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CGEN Stock trends
CGEN Stock performance
CGEN Stock analysis
CGEN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
